TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06092372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet intervention program
Description: Participants will get 5 meals/day based on their calorie needs minus 500 kcal/day less than their daily calorie expenditure. All meals will be tracked via a mobile application, including any meals outside the recommended food plan. The calories will be calculated based on the information provided.~To calculate the calories burned from any activities, all participants in the diet intervention arm will get an activity tracking device. The first calorie level is calculated based on the information in the registration form: age, height, weight, gender, and personal view of the daily activity. After that, and once the activity tracker is synced to the program, the calorie level is calculated based on the 7-day average calories burned.~The external diet intervention provider will be blinded to whether the study participants belong to the top or bottom 5% of the polygenic score for BMI.
Study: NCT05423158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: d-Coaching
Description: MOVN mobile app: Each participant will be assigned a secure login account that does not include personal information for research only. Participants will be trained on how to access and use the MOVN private social network group.~Annie text messaging: Participants will be registered in the Annie VA text messaging program to receive tailored, interactive push messages with a combination of 1 and 2-way tailored messages on goals, barriers, self-management, etc. (based on data collected in real-time from the Fitbit and barriers identified at baseline).~Fitbit wearable device \& mobile app: The intervention group will be instructed to use the Fitbit for step counts and maximizing the Fitbit mobile app/desktop platform to track all PA, sharing one's Fitbit profile with others (optional leaderboard), and use of all available features.
Study: NCT06174779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: Test drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study: NCT04912557

Intervention type: OTHER
Intervention: postoperative pain assess
Description: numerical pain scale and Metameric levels of cold insensitivity
Study: NCT05457244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-port robotic surgery
Description: Colorectal surgery using the da Vinci SP System will be performed via the umbilicus, McBurney's site or the reverse McBurney's site depending on the sites of lesion. All of these patients will undergo a standard minimally invasive resection in the same fashion as would be carried out with multiport laparoscopic or robotic surgery.
Study: NCT04816526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Descartes 08
Description: Car T-cells
Study: NCT06359002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYON4413
Description: BYON4413 will be administered by IV infusion.
Study: NCT05047094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks
Study: NCT05767450

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Vivomixx®
Description: The correct number of Vivomixx® sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The correct number of Placebo sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
Study: NCT06254599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-3505 Capsules
Description: A third-generation ALK tyrosine kinase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib Capsules
Description: An oral ALK tyrosine kinase inhibitor
Study: NCT05574634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet based adaptive multimodal attention practice program
Description: An adaptive at-home tablet-based program that includes variants of the Flanker Task, the Stroop Task, and a Visual Tracking Task. Each session of practice will include up to ten minutes with each of these task types, and the tasks will increase in difficulty in a way that further taxes attention (such as through more distractors or more incongruent trials) as participant performance improves.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet based adaptive criterion task practice program
Description: An adaptive, at-home tablet-based variant of the criterion task, that is, the selective attention/distraction task used during the scanning portion of the human participant portions of the study, that takes up to 25 minutes to complete each session.
Study: NCT04695080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine (MAVENCLAD®)
Description: Cladribine (MAVENCLAD®) 3.5mg/kg, administered as weight-adjusted 10mg tablets in two treatment courses (12 months apart) lasting 8- 10 days each.~Cladribine (MAVENCLAD®) 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as weight adjusted tablets in two treatment courses (12 months apart) lasting 8-10 days each.~Placebo 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets.
Study: NCT05799560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THERAPEUTIC TOUCH
Description: Therapeutic touch will be done. It will be applied twice a week for two weeks, each application for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REİKİ
Description: It will be applied twice a week for two weeks, each application for 20 minutes.
Study: NCT05497869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active release group
Description: Patient is in supine lying position with 15-20° shoulder abduction. Then place finger tips under Pectoralis minor tendon and position the arm in 90°/90° shoulder abduction and elbow flexion. Apply the pressure while stroking the tender area and ask the patient to adduct the arm then bring shoulder backward while maintain the pressure 3 sets of 10 repetition/ 4 days per week for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active control group
Description: Conventional treatment- includes gentle shoulder ROMs i.e. flexion, extension, abduction, adduction, internal rotation and external rotation with-in pain free range, 10 repetitions each for 3 times a day
Study: NCT05126602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 10000 IU
Description: Tablet of 5000 IU of vitamin D3 given twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 1000 IU
Description: Tablet of 1000 IU of vitamin D3 given once daily
Study: NCT05978661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FKC288
Description: Administration of FKC288 Four dose groups of 0.1×10\^6 CAR-T/kg, 0.3×10\^6 CAR-T/kg, 1.0×10\^6 CAR-T/kg, and 3.0×10\^6 CAR-T/kg FKC288 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.
Study: NCT06369129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orbital floor reconstruction with Patient Specific Zirconia Implant
Description: Orbital floor reconstruction with Patient Specific Zirconia Implant will be done

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orbital floor reconstruction with Patient Specific Titanium Implant
Description: Orbital floor reconstruction with Patient Specific Titanium Implant will be done
Study: NCT06054789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-33
Description: Subjects will receive one injection of 68Ga-PSMA-33/PSMA-617 (3-7mCi ), a PET radiopharmaceutical selective for Prostate-Specific Membrane Antigen. 68Ga-PSMA-33/PSMA-617 injection will be followed by a 10 ml saline flush.
Study: NCT05792046

Intervention type: DEVICE
Intervention: Visual field
Description: test for detecting loss in visual function
Study: NCT06231082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group one - percutaneous (P)
Description: Percutaneous procedure will be performed under standard conditions, under transabdominal ultrasound guidance. After choosing the optimum needle trajectory, the skin site will be marked, standard skin sterilization with iodine and surgical draping of the site will be performed. Local anesthesia of the site with gradual lidocaine solution infiltration of the skin and underlying planes will be performed. Under ultrasound guidance, with collaboration of the patient for the respiratory movements, one or two passages with a 16G needle will be performed (BARD Max Core 16G, Becton Dickinson, USA). Specimens will be collected in formalin and send to pathology for processing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group two - EUS FNB (E)
Description: EUS guided liver FNB will be performed under deep sedation with propofol under anesthesiology monitoring. A 19G gauge Franseen needle (Acquire 19G, Boston Scientific, USA) will be used with the wet suction technique. Before inserting into the operating channel, the stylet will be removed, and the needle will be primed with heparin (500UI/5ml). After liver puncture, the 20ml aspiration syringe will be attached. Three needle actuations will be performed, one or two passes in the left liver lobe. At the end of the 3rd actuation, the syringe aspiration will be stopped, the needle will be left in place in the liver parenchyma for 2 to 3 minutes. The liver needle path will be examined with Doppler ultrasound to look for possible bleeding. If present, about 25% of the needle content will be pushed in the liver path, as previously described - the blood patch technique.
Study: NCT06161272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: single

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib+Apatinib
Description: combination
Study: NCT06562751

Intervention type: OTHER
Intervention: Questionnaire
Description: Online questionnaire designed by the investigatory team.

Intervention type: OTHER
Intervention: Questionnaire
Description: Online questionnaire designed by the investigatory team.

Intervention type: OTHER
Intervention: Questionnaire
Description: Online questionnaire designed by the investigatory team.

Intervention type: OTHER
Intervention: Focus group
Description: Online focus group

Intervention type: OTHER
Intervention: Interview
Description: Online semi-structured interview

Intervention type: OTHER
Intervention: Workshop
Description: Online and face to face co-production workshops
Study: NCT04872400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 1 vial of Vancomycin 1g powder applied topically to the open fracture wound injury.
Study: NCT06054893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Description: Administered as specified in the treatment arm
Study: NCT06350604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project WHADE: A Partner-Based Physical Activity Program for Women
Description: Combination of behavioral, cognitive, social, and acceptance-based skills training to increase physical activity
Study: NCT04872400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Description: 1 vial of Tobramycin 1.2g powder applied topically to the open fracture wound injury.
Study: NCT04287608

Intervention type: DRUG
Intervention: dupilumab
Description: No investigational agents will be provided to study patients, and no specific treatment is required during the study. DUPIXENT®-treated patients will receive DUPIXENT as standard of care for the treatment of their AD, as prescribed by their physician. However, continuous treatment with dupilumab for at least 8 weeks is required as a condition for eligibility.

Intervention type: DRUG
Intervention: dupilumab
Description: No investigational agents will be provided to study patients, and no specific treatment is required during the study. DUPIXENT®-treated patients will receive DUPIXENT as standard of care for the treatment of their AD, as prescribed by their physician. However, continuous treatment with dupilumab for at least 8 weeks is required as a condition for eligibility.
Study: NCT05472649

Intervention type: BIOLOGICAL
Intervention: Gene-Modified Cell Therapy
Description: No investigational cell product will be administered
Study: NCT04934462

Intervention type: PROCEDURE
Group type: OTHER
Intervention: physiotherapy
Description: Six months physiotherapy aimed at hip stability.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: physiotherapy
Description: Six months physiotherapy aimed at hip stability.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: arthroscopy
Description: Arthroscopic plication of hip joint capsule.
Study: NCT06593327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Prevention Strategy
Description: Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.
Study: NCT06651658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleural embolisation
Description: Administration of pleural blood patch with tandem needle technique
Study: NCT06650696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCE promotion
Description: The intervention requires parents to complete a weekly parent-child interaction task online designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotiaonl skill enhancement
Description: This intervention combines online material with practical, emotion-focused activities. Participants will receive training online on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotiaonl skill enhancement
Description: This intervention combines online material with practical, emotion-focused activities. Participants will receive training online on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
Study: NCT06659289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efferon LPS
Description: Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~The hemoperfusion procedure is performed at the time of cardiopulmonary bypass during cardiac surgery. The therapy (Efferon LPS hemoperfusion) is performed once. The duration of the procedure is limited by the time ofcardiopulmonary bypass.
Study: NCT06601907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: alivis
Description: alivis is an interactive online program for independent use by users with Borderline Personality Disorder. It focuses on recognized treatment elements from Dialectical Behavior Therapy, Schema Therapy, Acceptance and Commitment Therapy, and Mindfulness Self-Compassion Therapy.
Study: NCT06610357

Intervention type: OTHER
Intervention: Group 1
Description: 42 diparetic children with cerebral palsy were included in the study. The Modified Ashworth Scale (MAS), the Children's Functional Independence Measure (WeeFIM)-Mobility section and the Gross Motor Function Measure-88 (GMFM-88) were applied before and after SDR surgery.
Study: NCT06610799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 Q3W Oxaliplatin 130 mg/m2，IV，Q3W, Capecitabine ,1000mg/ m2，PO，Bid，d1-14，Q3W
Study: NCT05707182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-rhPSMA-7.3
Description: 18F-rhPSMA-7.3 PET/MR
Study: NCT05788653

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thiele Massage
Description: Transvaginal Massage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse Friction Massage
Description: Transvaginal Massage
Study: NCT06368921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRT106
Description: intratumoral injection
Study: NCT04934475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase
Study: NCT06109623

Intervention type: OTHER
Intervention: observation
Description: To observe the changes and differences of steroid hormones between stress urinary incontinence group and control group.

Intervention type: OTHER
Intervention: observation
Description: To observe the changes and differences of steroid hormones between stress urinary incontinence group and control group.
Study: NCT04934475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: ASCT for ams B, C and D during consolidation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: ASCT for ams B, C and D during consolidation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: ASCT for ams B, C and D during consolidation
Study: NCT06109623

Intervention type: OTHER
Intervention: sex hormone
Description: Six indicators of steroid hormones (estrogen, testosterone, follicle stimulating hormone, luteinizing hormone, pituitary prolactin, progesterone)

Intervention type: OTHER
Intervention: sex hormone
Description: Six indicators of steroid hormones (estrogen, testosterone, follicle stimulating hormone, luteinizing hormone, pituitary prolactin, progesterone)
Study: NCT06087406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imvotamab
Description: Administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride administered intravenously
Study: NCT06142383

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: S.C. Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XXB750 Low dose
Description: S.C. Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XXB750 Medium Dose
Description: S.C. Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XXB750 High Dose
Description: S.C. Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril/valsartan
Description: Tablet
Study: NCT06405139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine
Description: Nanoliposomal irinotecan 60mg/m2; Oxaliplatin 85 mg/m2; Capecitabine 800 mg/m2 twice daily, day 1 to 7; repeated every two weeks.
Study: NCT05588778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ¡En Forma y Fuerte! @home/en casa
Description: The ¡En Forma y Fuerte! Program. ¡En Forma y Fuerte! is designed to be delivered in Spanish by bilingual, bicultural, qualified exercise instructors. Instructors are required to have an exercise instructor/specialist certification through a national organization such as the American College of Sports Medicine, American Council on Exercise, or Aerobics and Fitness Association of America, or to have an undergraduate degree in an exercise science related field. The 8 hour training uses both didactic and hands-on role modeling for delivering both the exercise and health education components of the program. Instructors in the online version will also participate in a 60 minute training designed for this new version of the program. We have previously developed an asynchronous, online instructor training for the customary program and will translate it to Spanish for this proposal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ¡En Forma y Fuerte! @home/en casa
Description: The ¡En Forma y Fuerte! Program. ¡En Forma y Fuerte! is designed to be delivered in Spanish by bilingual, bicultural, qualified exercise instructors. Instructors are required to have an exercise instructor/specialist certification through a national organization such as the American College of Sports Medicine, American Council on Exercise, or Aerobics and Fitness Association of America, or to have an undergraduate degree in an exercise science related field. The 8 hour training uses both didactic and hands-on role modeling for delivering both the exercise and health education components of the program. Instructors in the online version will also participate in a 60 minute training designed for this new version of the program. We have previously developed an asynchronous, online instructor training for the customary program and will translate it to Spanish for this proposal.